4  Actions in the Islets: β-Cells and α-Cells

The pancreatic islets (islets of Langerhans) contain β-cells that release insulin, α-cells that release glucagon, δ-cells that release somatostatin, and others, and these cells influence one another (paracrine regulation). GLP-1 and GIP act on all three cell types.

4.1 β-cells: insulin secretion

As seen in Chapter 3, both GLP-1 and GIP enhance insulin secretion in a glucose-dependent manner. Besides acute stimulation of secretion, they have the following actions.

Action GLP-1 GIP Notes
Enhanced insulin secretion (glucose-dependent) ◎ ◎ Response to GIP is reduced in type 2 diabetes
Insulin biosynthesis (gene transcription, translation)↑ ◎ ○ Replenishes stores depleted by secretion
β-cell proliferation, suppression of apoptosis ○ ○ Mainly rodent data. An increase in β-cell mass has not been confirmed in adult humans
CautionThe gap between animal data and humans

You often hear that “GLP-1 increases β-cells”, but much of the evidence comes from experiments in young rodents. Adult human β-cells have very low proliferative capacity, and an increase in β-cell mass with GLP-1RAs has not been shown in humans. The improvement in β-cell function seen clinically is thought to be mainly due to relief of the burden of hyperglycemia (glucotoxicity) and functional improvement.

4.2 α-cells: here GLP-1 and GIP are opposite

One of the biggest differences between GLP-1 and GIP is their action on glucagon.

GLP-1 GIP
Glucagon secretion Suppressed (during hyperglycemia) Stimulated (especially at low-to-normal glucose)
Receptors on α-cells Few (mainly indirect action) Many (direct action)

flowchart LR
  subgraph GLP1["GLP-1"]
    direction TB
    g1["GLP-1"] --> d1["δ-cells<br/>somatostatin↑"]
    g1 --> b1["β-cells<br/>insulin↑"]
    d1 -->|"inhibits"| a1["α-cells<br/>glucagon↓"]
    b1 -->|"inhibits"| a1
  end
  subgraph GIP["GIP"]
    direction TB
    g2["GIP"] --> a2["α-cells (many GIPR)<br/>glucagon↑"]
    g2 --> b2["β-cells<br/>insulin↑"]
  end

4.2.1 Glucagon suppression by GLP-1

Because α-cells express almost no GLP-1R, GLP-1’s suppression of glucagon is mainly indirect.

  • GLP-1R on δ-cells → somatostatin secretion↑ → inhibits α-cells
  • Inhibition by insulin, zinc, etc. from β-cells

This suppression is also glucose-dependent and does not interfere with glucagon secretion during hypoglycemia (a response essential for recovery from hypoglycemia).

4.2.2 Glucagon stimulation by GIP: why would it do that?

You may think, “Isn’t it contradictory to release glucagon when we want to lower blood glucose?” Physiologically, it can be understood as follows.

  • During hyperglycemia: GIP strongly promotes insulin secretion (its glucagon-stimulating action is inconspicuous)
  • At low-to-normal glucose: GIP releases little insulin and instead releases glucagon
  • With a meal centered on fat and protein (a low-carbohydrate meal), releasing only insulin could cause hypoglycemia. Releasing glucagon at the same time stabilizes blood glucose — this is thought to be the purpose

In other words, GIP can be regarded as a “bidirectional glucose-stabilizing hormone” that adjusts the balance between insulin and glucagon according to the blood glucose level.

NoteCan be a problem in type 2 diabetes

In type 2 diabetes, the insulinotropic action of GIP weakens while its glucagon-stimulating action remains. Therefore, physiological GIP may act in the direction of worsening hyperglycemia in type 2 diabetes, which is one of the reasons it was long thought that “GIP can’t be made into a drug”.

4.3 Looking at the islet as a whole

flowchart LR
  Meal["After a meal<br/>blood glucose↑"] --> Inc["GLP-1 / GIP↑"]
  Inc --> Ins["Insulin↑"]
  Inc --> GlcgN["Glucagon<br/>GLP-1: ↓ / GIP: depends on glucose"]
  Ins --> Liver["Liver<br/>gluconeogenesis, glycogenolysis↓"]
  GlcgN --> Liver
  Ins --> Muscle["Muscle, fat<br/>glucose uptake↑"]
  Liver --> BG["Curbs the postprandial rise in blood glucose"]
  Muscle --> BG

Lowering blood glucose is not just about “increasing insulin”; “reducing glucagon to suppress glucose output from the liver” is equally important. A substantial part of the glucose-lowering effect of GLP-1RAs is thought to be due to this glucagon suppression.

4.4 Summary

  • β-cells: both GLP-1 and GIP increase insulin secretion in a glucose-dependent manner and increase insulin biosynthesis
  • α-cells: GLP-1 lowers glucagon (indirect action via δ-cells and β-cells), GIP raises glucagon (direct action, especially during hypoglycemia)
  • GIP is a “bidirectional” hormone that uses insulin and glucagon selectively according to the blood glucose level
  • The β-cell proliferative action is mainly rodent data and has not been confirmed in adult humans